Survey of Clinical Protocols for the Use of 177Lu-PSMA-617 in the United States

Phillip H. Kuo; Matthew F. Covington; Daniel J. Lee; Terence Z. Wong; Neeta Pandit-Taskar

doi:10.2967/jnmt.123.266769

Survey of Clinical Protocols for the Use of ¹⁷⁷Lu-PSMA-617 in the United States

Phillip H. Kuo
, Matthew F. Covington
, Daniel J. Lee
, Terence Z. Wong
, Neeta Pandit-Taskar

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Although guidelines for the use of ¹⁷⁷Lu-PSMA-617 published by various organizations are important, they do not include all the essential, practical points necessary for a complete institutional protocol. Therefore, a brief survey was performed to assess key components of the ¹⁷⁷Lu-PSMA-617 protocol before, during, and after delivery of therapy. This survey demonstrated the wide variability in many aspects of institutional protocols regarding determination of eligibility for and administration of ¹⁷⁷Lu-PSMA-617 therapy. The real-world protocol details provided here from a variety of institutions may help new and established theranostic programs.

Original language	English (US)
Pages (from-to)	208-211
Number of pages	4
Journal	Journal of nuclear medicine technology
Volume	52
Issue number	3
DOIs	https://doi.org/10.2967/jnmt.123.266769
State	Published - Sep 1 2024

Keywords

PSMA
lutetium
protocol
survey
theranostics

ASJC Scopus subject areas

Radiological and Ultrasound Technology
Radiology Nuclear Medicine and imaging

Access to Document

10.2967/jnmt.123.266769

Cite this

@article{34f1f450d95041579a87d385078e5eb8,

title = "Survey of Clinical Protocols for the Use of 177Lu-PSMA-617 in the United States",

abstract = "Although guidelines for the use of 177Lu-PSMA-617 published by various organizations are important, they do not include all the essential, practical points necessary for a complete institutional protocol. Therefore, a brief survey was performed to assess key components of the 177Lu-PSMA-617 protocol before, during, and after delivery of therapy. This survey demonstrated the wide variability in many aspects of institutional protocols regarding determination of eligibility for and administration of 177Lu-PSMA-617 therapy. The real-world protocol details provided here from a variety of institutions may help new and established theranostic programs.",

keywords = "PSMA, lutetium, protocol, survey, theranostics",

author = "Kuo, \{Phillip H.\} and Covington, \{Matthew F.\} and Lee, \{Daniel J.\} and Wong, \{Terence Z.\} and Neeta Pandit-Taskar",

note = "Publisher Copyright: {\textcopyright} 2024 by the Society of Nuclear Medicine and Molecular Imaging.",

year = "2024",

month = sep,

day = "1",

doi = "10.2967/jnmt.123.266769",

language = "English (US)",

volume = "52",

pages = "208--211",

journal = "Journal of nuclear medicine technology",

issn = "0091-4916",

publisher = "Society of Nuclear Medicine Inc.",

number = "3",

}

TY - JOUR

T1 - Survey of Clinical Protocols for the Use of 177Lu-PSMA-617 in the United States

AU - Kuo, Phillip H.

AU - Covington, Matthew F.

AU - Lee, Daniel J.

AU - Wong, Terence Z.

AU - Pandit-Taskar, Neeta

PY - 2024/9/1

Y1 - 2024/9/1

N2 - Although guidelines for the use of 177Lu-PSMA-617 published by various organizations are important, they do not include all the essential, practical points necessary for a complete institutional protocol. Therefore, a brief survey was performed to assess key components of the 177Lu-PSMA-617 protocol before, during, and after delivery of therapy. This survey demonstrated the wide variability in many aspects of institutional protocols regarding determination of eligibility for and administration of 177Lu-PSMA-617 therapy. The real-world protocol details provided here from a variety of institutions may help new and established theranostic programs.

AB - Although guidelines for the use of 177Lu-PSMA-617 published by various organizations are important, they do not include all the essential, practical points necessary for a complete institutional protocol. Therefore, a brief survey was performed to assess key components of the 177Lu-PSMA-617 protocol before, during, and after delivery of therapy. This survey demonstrated the wide variability in many aspects of institutional protocols regarding determination of eligibility for and administration of 177Lu-PSMA-617 therapy. The real-world protocol details provided here from a variety of institutions may help new and established theranostic programs.

KW - PSMA

KW - lutetium

KW - protocol

KW - survey

KW - theranostics

UR - https://www.scopus.com/pages/publications/85203420218

UR - https://www.scopus.com/pages/publications/85203420218#tab=citedBy

U2 - 10.2967/jnmt.123.266769

DO - 10.2967/jnmt.123.266769

M3 - Article

C2 - 39237335

AN - SCOPUS:85203420218

SN - 0091-4916

VL - 52

SP - 208

EP - 211

JO - Journal of nuclear medicine technology

JF - Journal of nuclear medicine technology

IS - 3

ER -